Literature DB >> 18020977

The parkin protein as a therapeutic target in Parkinson's disease.

Konstanze F Winklhofer1.   

Abstract

Parkinson's disease (PD) is the most common movement disorder and the second most common neurodegenerative disease after Alzheimer's disease, affecting an increasing number of patients due to the demographic trend towards an aged population. The etiology of sporadic PD is only poorly understood, thus, the identification of genes that are responsible for familial variants of PD was a major breakthrough. Insight into the function of these genes can promote the understanding of the molecular causes of PD and help to focus research on key biochemical pathways. Mutations in the parkin gene, encoding an E3 ubiquitin ligase, are responsible for the majority of autosomal recessive PD. Recent research revealed that parkin has a remarkably wide neuroprotective capacity, preventing cell death under various stress conditions. This property makes parkin an attractive target for therapeutic strategies to prevent or halt the loss of dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020977     DOI: 10.1517/14728222.11.12.1543

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  7 in total

Review 1.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 2.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

3.  Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector.

Authors:  Anke Van der Perren; Cindy Casteels; Koen Van Laere; Rik Gijsbers; Chris Van den Haute; Veerle Baekelandt
Journal:  J Vis Exp       Date:  2016-02-28       Impact factor: 1.355

Review 4.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 5.  Defective autophagy in Parkinson's disease: lessons from genetics.

Authors:  H Zhang; C Duan; H Yang
Journal:  Mol Neurobiol       Date:  2014-07-04       Impact factor: 5.590

Review 6.  Therapeutic approaches in Parkinson's disease and related disorders.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 7.  Post translational modification of Parkin.

Authors:  Joy Chakraborty; Valentina Basso; Elena Ziviani
Journal:  Biol Direct       Date:  2017-02-21       Impact factor: 4.540

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.